| Identification | Back Directory | [Name]
NS 3623 | [CAS]
343630-41-1 | [Synonyms]
NS 3623
1-[4-bromo-2-(2H-tetrazol-5-yl)phenyl]-3-[3-(trifluoromethyl)phenyl]urea
N-[4-Bromo-2-(1H-tetrazol-5-yl-phenyl]-N'-[3-(trifluoromethyl)phenyl]-urea | [Molecular Formula]
C15H10BrF3N6O | [MOL File]
343630-41-1.mol | [Molecular Weight]
427.18 |
| Chemical Properties | Back Directory | [density ]
1.759±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble to 100 mM in DMSO | [form ]
Powder | [pka]
3.95±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
NS 3623 selectively activates the human ether-a-go-go related gene (hERG) potassium channel which mediates the repolarizing cardiac current IKr. NS 3623 an IKr agonist, cause QT interval prolongation, increasing the risk of dangerous ventricular fibrillations, eventually leading to sudden cardiac death. | [Biological Activity]
NS3623 is a potent and selective activator of KV11.1 (hERG) and KV4.3 channels. It activates the IKr and Ito currents and exhibits antiarrhythmic activity. NS3623 may also act as a partial blocker of KV11.1 channels. | [in vivo]
NS3623 (30 mg/kg; i.v.; lasting for 3 minutes) shortens the corrected QT interval by 25 +/- 4% in anaesthetized guinea pigs[1].
NS3623 (50 mg/kg) shortenes the QT interval by 30 +/- 6% in conscious guinea pigs. NS3623 (50 mg/kg) immediately decreases the QTcF interval and remains significantly shortened for approximately 30 minutes[1]. | Animal Model: | Anesthetized guinea pig[1] | | Dosage: | 30 mg/kg | | Administration: | Intravenous injection; lasting for 3 minutes | | Result: | Shortened the corrected QT interval by 25 +/- 4%. |
| [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|